ArticleNPJ breast cancer2025
Nomogram for predicting axillary pathologic complete response in cN2-3 breast cancer after neoadjuvant chemotherapy.
Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Nodal Pathologic Response After Neoadjuvant Systemic Therapy in Clinically Advanced Node-Positive (cN2 and cN3) Breast Cancer.Annals of surgical oncology · 2026Article
- Review
- Multimodal nomogram for predicting axillary pathological complete response after neoadjuvant therapy in clinically node-positive breast cancer.Frontiers in oncology · 2026Article
- Advances in ultrasound for preoperative molecular subtyping of malignant breast tumors.Frontiers in oncology · 2026Review
- Development of a nomogram for predicting axillary pathologic complete response after neoadjuvant therapy in clinically node-positive breast cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
We aimed to predict axillary pathologic complete response (pCR) in patients with clinical N2-3 breast cancer who underwent neoadjuvant chemotherapy (NAC) followed by breast and axillary surgeries. These patients were retrospectively analyzed between 2016 and 2020. Imaging metrics (lesion size and reduction ratios measured using magnetic resonance imaging (MRI) and ultrasonography (US)) and clinical and pathological factors were analyzed. Axillary pCR was achieved in 49.3% (n = 136/276) of the patients. Post-NAC significant predictors included breast lesion and lymph node (LN) sizes on MRI and LN cortical thickness on US. Pre-NAC tumor-specific factors were also associated with axillary pCR. In multivariable logistic regression analyses using three models, Model 3 (imaging variables, tumor characteristics, and molecular subtypes) demonstrated the best predictive performance (AUC: 0.9). Integrating molecular subtype-specific imaging and tumor characteristics enabled precise prediction of axillary pCR in patients with cN2-3 breast cancer, supporting tailored surgical approaches based on individual responses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.